

1 **Superior long-term patency of no-touch vein graft compared to conventional vein grafts**
2 **in over 1500 consecutive patients**

3
4
5 Gabriele Ferrari, MD^{1, 2}, Richard Loayza, MD¹, Ava Azari, MD¹, Håkan Geijer, MD, PhD³,
6 Yang Cao, PhD⁴, Roland Carlsson, MD, PhD⁵, Leif Bojö, MD, PhD⁶, Ninos Samano, MD,
7 PhD¹, Domingos Souza, MD, PhD¹

8
9 ¹University Health Care Research Centre, Faculty of Medicine and Health, Örebro
10 University, Örebro, Sweden; ²Department of Cardiology and Cardiothoracic Surgery,
11 Blekinge Hospital, Karlskrona, Sweden; ³Department of Radiology, Faculty of Medicine and
12 Health, Örebro University, Örebro, Sweden; ⁴Clinical Epidemiology and Biostatistics, School
13 of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden;
14 ⁵Svensk PCI AB, Regional Hospital of Karlstad, Karlstad, Sweden; ⁶Clinical Physiology
15 Division, Regional Hospital of Karlstad, Karlstad, Sweden.

16
17 **Short title: Patency of no-touch and conventional vein grafts**

18
19 **Corresponding author:** Dr. Gabriele Ferrari

20 **Address:** Department of Cardiology and Cardiothoracic surgery, Blekinge Hospital, 37181
21 Karlskrona, Sweden.

22 **Office:** +46 455736897

23 **Fax:** +46 455731051

24 **E-mail:** gabriele.ferrari@regionblekinge.se

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 **ABSTRACT**

27 **Objectives:** To evaluate the long-term angiographic patency of saphenous vein grafts (SVG)
28 harvested using the no-touch technique compared to the conventional technique.

29 **Methods:** This was a single-center, retrospective, cohort study. The inclusion criteria were
30 individuals who underwent a CABG (coronary artery bypass grafting) between January 1995
31 and July 2020, and who successively needed a clinically-driven angiography. The primary
32 endpoint was long-term patency. The secondary endpoints were differences in patency based
33 on sub-group analysis (single vs. sequential graft, divided by target vessel).

34 **Results:** The study included 1520 individuals (618 no-touch, 825 conventional and 77
35 arterial grafts). The mean clinical follow-up time was 8.4 years \pm 5.5 years. The patency per
36 patient was 70.7% in the no-touch grafts vs. 46.7% in the conventional grafts ($p < 0.001$, OR
37 = 2.8). The graft patency was 75.9% in the no-touch grafts vs. 62.8% in the conventional
38 grafts ($p < 0.001$, OR= 1.8).

39 **Conclusions:** The no-touch vein grafts were associated with statistically significantly higher
40 patency at long-term compared to the conventional grafts.

41

42 **Clinical Trial Registration:** NCT04656366, 7 December 2020

43

44 **Non-standard abbreviations and non-standard acronyms**

45 A: arterial graft

46 BMS: bare metal stent

47 C: conventional

48 CABG: coronary artery bypass grafting

49 DA: diagonal artery

50 DAPT: double antiplatelet therapy

51 DES: drug-eluting stent

52 EF: ejection fraction

53 FFR: fractional flow reserve

54 iFR: instantaneous wave-free ratio

55 IQR: interquartile range

56 LAD: left anterior descending artery

57 LITA: left internal thoracic artery

58 MA: marginal artery

59 MACE: major adverse cardiac events

60 MI: myocardial infarction

61 NT: no-touch

62 OR: odds ratio

63 PCI: percutaneous coronary intervention

64 RCA: right coronary artery

65 RITA: right internal thoracic artery

66 SD: standard deviation

67 SVG: saphenous vein graft

68 TIMI: thrombolysis in myocardial infarction

69 TVR: target vessel revascularization

70 **Clinical Perspective**

71 - **What is new?**

72 ➤ The largest follow-up of the patency of no-touch vein grafts in the
73 international literature.

74 ➤ Patients with a no-touch vein graft had significantly better patency ($p < 0.001$)
75 at mean follow-up of more than 8 years.

76 - **What are the clinical implications?**

77 ➤ Consequent reduction in cardiovascular events after no-touch vein graft.

78 ➤ Benefits at individual level due to fewer episodes of re-angina and myocardial
79 infarction, and fewer coronary interventions.

80 ➤ Benefits at community level due to fewer re-hospitalizations and a reduction
81 in healthcare costs.

82

83 **Introduction**

84 Ischemic heart disease is the leading cause of death worldwide, accounting for almost 8.9
85 million deaths in 2019 ¹. The main treatment options are percutaneous coronary intervention
86 (PCI), coronary artery bypass grafting (CABG) and, in some cases, both. The choice of
87 treatment depends on the clinical presentation, grade of disease, type of lesion, and patient
88 comorbidities. Guidelines ²⁻⁴ recommend CABG in cases of multivessel disease or left main
89 stem, and/or diabetes mellitus, to improve survival and reduce the risk of major adverse
90 cardiac events (MACE) ⁵⁻⁹, which are defined as death, myocardial infarction (MI), in-stent
91 restenosis, and/or repeated target vessel revascularization (TVR). The grafts used, especially
92 vein grafts, are subject to remodelling and progressive intimal hyperplasia and
93 atherosclerosis, which may lead to graft stenosis or occlusion and thereby limit the graft
94 patency ⁷. These events occur more frequently and rapidly in saphenous vein grafts (SVGs)
95 compared to left internal thoracic artery (LITA) or other arterial grafts ^{8,9}. Graft patency after
96 CABG is a major determinant of clinical prognosis and long-term survival ⁷.

97 The no-touch (NT) technique ¹⁰ differs from the conventional technique in that it is associated
98 with less endothelium damage during the harvesting procedure ^{11,12} and leads to reduced neo-
99 intimal hyperplasia and subsequent atherosclerosis in the long term ^{13,14}.

100 The aim of this study was to evaluate the long-term angiographic patency of saphenous vein
101 grafts (SVG) harvested using the NT technique compared to the conventional technique.

102 This is a single-center, retrospective, cohort study. The study complied with the STROBE
103 (STrengthening the Reporting of OBServational studies in Epidemiology) statement and the
104 STROBE checklist was used ¹⁵.

105

106 **Material and Methods**

107 *Data collection*

108 This single-center study included all individuals treated with a CABG between January 1,
109 1995 and June 30, 2020 at our Cardiothoracic Department and who successively needed a
110 clinically driven-angiography. The study was a single-center study involving a center with
111 long experience with the NT technique having used it for harvesting the saphenous vein since
112 1990. The study was performed in accordance with the Declaration of Helsinki. The Regional
113 Ethical Review Board approved the study (Dnr 2020/04168).

114 The standard operation in our center has been to anastomise the LITA to the LAD (left
115 anterior descending) and vein grafts to the other target vessels; in some cases, total arterial
116 revascularization (A) occurred. The SVG was harvested either with the NT or with the C
117 technique, as previously described¹⁶. The type of technique used was chosen by the surgeon
118 at the time of operation based on individual assessment and, therefore, without
119 randomization. The angiographies were performed in two cardiology departments and were
120 clinically driven, being due to either angina or myocardial infarction. No planned
121 angiographic follow-up was performed. No exclusion criterion was defined.

122 The grade of stenosis and its significance was defined according to the 2021 American Heart
123 Association for coronary artery revascularization¹⁷. A limit of 70% was set for the non-left
124 main stenosis and 50% for the left main stenosis or for graft stenosis; in case of doubt, the
125 severity of the lesion was confirmed using the FFR (fractional flow reserve) or the iFR
126 (instantaneous wave-free ratio).

127 The operative data (CABG) and the procedural data were collected with the help of an
128 intervention-related quality register (the Swedish cardiological and cardiosurgical
129 intervention register Swedeheart)¹⁸. The operative data regarding the type of vein graft, the
130 number of anastomoses, and the target vessel for the peripheral anastomosis were extracted

131 and double checked by reviewing records in the clinical software of the two hospitals
132 involved.

133

134 *Statistical methods*

135 The primary endpoint was defined as long-term patency.

136 Secondary outcomes were the differences between single grafts and sequential grafts, and the
137 different territories fed by the stenosed vein graft based on sub-group analyses.

138 Descriptive statistics were calculated as means \pm standard deviations (SD) for normally
139 distributed variables, as median with interquartile range (IQR) for non-normally distributed
140 variables, and as count with percentage for categorical variables.

141 The Chi-squared test (or Fisher's exact test for an expected count lower than 5) was used to
142 compare categorical proportions between the two groups (NT and C). The unpaired t-test was
143 performed to compare continuous variables and the Mann-Whitney U-test was used in cases
144 of non-normally distributed data.

145 Statistical analyses were performed using SPSS version 27.0 (IBM, Armonk, NY, USA).

146

147 **Results**

148 Between January 2006 and July 2020, 1571 individuals who had previously been treated with
149 CABG needed an angiography (Figure 1). Fifty-one were lost at follow-up due to the
150 inability to access the surgical reports (i.e., microfilm not available, journal lost, data
151 protection).

152 The study included 1520 consecutive patients (618 NT, 825 C, 77 A) who needed a
153 postoperative angiography (see Figure 1 and Table 1) with a mean follow-up time of $8.4 \pm$
154 5.5 years and up to 24.7 years. The study analysed 2564 venous grafts (908 NT, 1656 C),
155 Table 2.

156 In 29 cases, the angiography was only diagnostic and no new stenosis was detected. In 614

157 cases, stenoses were present in at least one vein graft. One hundred and thirty individuals
158 presented with a stenosis in an arterial graft, and in 747 cases the new stenosis affected only
159 the native vessels.

160

161 *Demographic, operative, and procedural characteristics*

162 A total of 1443 individuals received an SVG at surgery (618 NT, 825 C). The demographic,
163 operative and angiographic characteristics of this group are summarized in Table 3. The
164 demographic characteristics of the two groups were similar and patients had a comparable
165 age at the time of CABG (63.2 ± 8.6 years NT, 63.1 ± 21.1 years C; $p = 0.893$; Table 3); most
166 of the patients were male (78.5%). The risk factor distribution showed a significantly higher
167 rate of hypertension (89% NT vs. 83.3% C) and hypercholesterolemia (91.7% NT vs. 84% C)
168 in the NT group ($p < 0.001$). Fewer patients with an NT SVG received a post-operative
169 DAPT (dual anti platelet therapy), 35.4% NT vs. 44% C ($p = 0.001$).

170 The operative characteristics regarding number of peripheral anastomoses were similar in the
171 two groups (Table 4). No differences regarding the indication for the new angiography were
172 presented ($p = 0.916$), Table 4.

173 The mean follow-up time was 5.5 ± 4.4 years for the individuals with an NT SVG and $10.7 \pm$
174 5.1 years for the individuals with a C SVG.

175

176 *Clinical follow-up*

177 Primary endpoint

178 The total patency rate per patient was 70.7% (437/618) in the NT group and 46.7% (385/825)
179 in the C group ($p < 0.001$), with an OR (odds ratio) of 2.8, Table 5.

180 The patency rate per graft was 75.9% (609/908) in the NT group and 63.5% (1051/1656) in
181 the C group ($p < 0.001$), with an OR of 1.8, Table 6.

182

183 Secondary endpoint

184 *Single grafts vs. sequential grafts*

185 In the analysis of the different types of graft received (single or sequential), there was a
186 statistically significant higher patency in the NT group both for single grafts (75.6% NT vs.
187 62.8% C, $p < 0.001$) and for sequential grafts (76.0% NT vs. 65.3% C, $p < 0.001$), Table 6.

188

189 *Territories fed by the stenosed vein graft*

190 The subgroup analysis, divided by distal anastomosis, revealed statistically significantly
191 better results for the NT grafts for each of the different distribution territories, Table 7. The
192 patency of the NT SVGs was over 80% if the target vessel was a coronary of the left system,
193 and around 70% if the target vessel was the right coronary artery (RCA). In contrast, the
194 patency of the C SVGs was as low as 57% if the target vessel was the RCA, and never
195 reached 80% in the left system. The differences between the NT and the C in the four
196 different territories of distribution were significant even when analysing the single and the
197 sequential grafts separately; however, the exceptions were the single grafts to the marginal
198 artery (MA), the sequential ones to RCA, and both types to the left anterior descending
199 (LAD) due to the limited number of included individuals, Table 7.

200

201 *Patency of arterial grafts*

202 The long-term patency of the total arterial grafts was 86.3% and of the LITA grafts 96.2%.
203 The patency rates for arterial grafts were similar regardless of whether the patients received
204 an SVG or not, Table 5.

205

206

207 **Discussion**

208 This study presents the results from the largest long-term follow-up investigation of the

209 patency of NT SVGs.

210 The main finding of this study was higher graft patency at follow-up of the NT grafts
211 (75.9%), compared to the C grafts (63.5%); $p < 0.001$. The superiority of the NT SVG was
212 shown even when the different types of grafts (single vs. sequential) and the different types of
213 territory of distribution were analysed. It has to be mentioned that NT grafts have shorter
214 follow-up compared to the C grafts; however, this is due to higher rates of restenosis in the
215 native vessels and not in the SVGs themselves.

216

217 It is known that C SVGs have high risks of thrombosis, intimal hyperplasia, and early
218 atherosclerosis, which all lead to graft occlusion rates of up to 50-60% after 10 years,
219 according to most clinical records ¹⁹⁻²¹.

220 Our study showed similar results for the C grafts with a patency per patient of only 46.7% at
221 a mean follow-up of 8.4 years. The NT grafts, on the other hand, present a patency per patient
222 of more than 70% at follow-up (OR of 2.8) and of almost 76% per graft.

223 Several studies ^{11, 13, 14, 16, 22-25} have shown the superiority of NT SVGs compared to C SVGs
224 on follow-up at a mean time up to 16 years ¹⁴. Previous studies have, however, had either a
225 limited follow-up time of maximum 1 year ^{22, 23, 25} or included a limited number of patients
226 (fewer than 300) ^{11, 13, 14, 16, 23, 24}. The present study is the first to include both a large cohort,
227 more than 1500 individuals, and a mean follow-up time of more than 5 years and up to almost
228 25 years. The higher long-term patency of NT SVGs may play an important role in reduced
229 long-term MACE and re-hospitalization rates.

230

231 In our previous study ²⁶ we noted a very limited number of patients with NT SVGs being
232 treated with PCI compared to C (63 NT vs. 246 C). We also noted that almost 70% of
233 patients who needed a coronary angiography after the CABG operation did not receive a PCI
234 on their vein graft. The present study gives an explanation for these observations; more than

235 half (57.6%) of the patients with an NT SVG who needed a postoperative angiography did
236 not have a SVG stenosis, but presented with a new stenosis in the native vessels. This
237 occurred in only 39.6% of patients with a C SVG.

238 Another interesting data is the higher percentage of sequential grafts in the NT group (49.3%
239 vs. 24.7%). This is possible thanks to the qualities of the NT grafts that are much less prone
240 to kinking when performing multiple anastomoses ¹², comparing the C technique.

241

242 As previously mentioned, NT grafts have a shorter time to follow-up compared to C grafts,
243 with only 23 cases (vs. 124) needing an angiography more than 15 years after the operation.

244 This shorter follow-up time for NT grafts is due to a lower patency rate of native vessels in
245 these individuals. A possible explanation is the statistically significant difference (35.4% vs
246 44.0%, $p = 0.001$) in the use of DAPT, with NT grafts receiving postoperative DAPT in
247 fewer cases compared to C grafts. The benefits of DAPT after an acute coronary syndrome,
248 in terms of reduced risk of restenosis and higher short- and long-term patency rates, are well
249 known and supported by the international guidelines ²⁷. Another possible explanation is that
250 in the 1990's, the C graft was used in most cases so these patients automatically have a longer
251 follow-up time than the NT grafts.

252

253 The main limitation of this study is that it is non-randomized and the choice of graft type was
254 dependent on the surgeon's choice. Another limitation is the different follow-up times in the
255 two groups.

256

257 *Conclusions*

258 The results regarding the NT SVGs are encouraging, with statistically significantly higher
259 patency at long-term follow-up compared to a C SVG, and with an almost 50% reduction in
260 cases of vein graft stenosis long-term.

261 The results suggest an important reduction of cardiovascular events if the patients receive
262 comparable medical treatment post-surgery and if the management of the risk factors follows
263 the guidelines.

264 Randomized studies are needed to evaluate the performance and benefits of NT SVGs at both
265 individual (better patency and fewer coronary interventions) and community (fewer re-
266 hospitalizations) levels.

267

268 **Acknowledgements:** We thank research assistant Ulf Graf for help with the database
269 settings.

270

271 **Sourcing of Fundings:** This work was supported by Region Örebro County through the
272 regional research board (grant OLL- OLL-935188, 18 January 2020).

273

274 **Disclosures:** None.

275

276 **Supplementary Files**

277 Supplementary Table S1

278 Supplementary Table S2

279 Supplementary Table S3

280

281 **Author contribution statement**

282 Gabriele Ferrari, Håkan Geijer, Ninos Samano, Domingos Souza, Roland Carlsson and Leif
283 Bojö devised the original concept of this study. Gabriele Ferrari, Håkan Geijer, Ninos
284 Samano, Domingos Souza, Roland Carlsson and Leif Bojö designed the study. Gabriele
285 Ferrari, Richard Loayza and Ava Azari collected the patient data. Gabriele Ferrari, Richard
286 Loayza and Ava Azari performed the statistical analysis. Yang Cao provided support for
287 statistical analysis and result explanation. Gabriele Ferrari, and Yang Cao wrote the first draft
288 of the manuscript. All authors reviewed the manuscript, contributed significantly to its critical
289 review, and approved the final version.

290

291 **Figure legends**

292 Figure 1: STROBE flowchart of the individuals included in the study

293

294 Table 1: Graft characteristics of the patients in the total population

Patient characteristics	N (%)
No-touch	618 (40.7)
Conventional	825 (54.3)
LITA to LAD	1273 (83.8)
RITA or Radial	144 (9.5)
Total Arterial	77 (5.1)
No-touch single grafts	203 (13.4)
No-touch sequential grafts	415 (27.3)
Conventional single grafts	450 (29.6)
Conventional sequential grafts	375 (24.7)

295

296 Table 2: Vein graft characteristics of the two groups

297	Patient characteristics	No-touch	Conventional
	No. total grafts	908	1656
	No. single grafts	463	1247
	No. sequential grafts	445	409

298 Table 3: Demographic characteristics of the individuals who received a saphenous vein graft

Patient characteristics	No-touch	Conventional	p-value
No. of patients, n (%)	618 (40.7)	825 (54.3)	
Mean age at CABG, years \pm SD	63.2 \pm 8.6	63.1 \pm 21.1	0.893
Male, n (%)	506 (81.9)	626 (75.9)	0.006
Hypertension, n (%)	550 (89.0)	687 (83.3)	<0.001
Hypercholesterolemia, n (%)	567 (91.7)	693 (84.0)	<0.001
Diabetes mellitus, n (%)	216 (39.8)	284 (34.4)	0.895
Smoking, n (%)	349 (56.5)	440 (53.3)	0.359
Double platelet inhibitor therapy, n (%)	219 (35.4)	363 (44.0)	0.001
Creatinine median (Q1, Q3)	85 (72, 102)	88 (75, 105)	0.004*
Dead at follow-up, n (%)	170 (27.5)	420 (50.9)	<0.001

299 * Mann-Whitney U test was used. T-test was used for continuous variables and Chi-squared
300 test for categorical variables. Values are presented as mean \pm standard deviation for normal
301 distributed variables, median (Q1, Q3) for non-normal distributed variables, or n (%). Ages
302 and times are given in years. Creatinine is given in micromole/L.

303

304 Table 4: Operative and procedural characteristics of the individuals who received a
305 saphenous vein graft

Patient characteristics	No-touch	Conventional	p-value
No. of patients	618	825	
No. of grafts	908	1656	
No. of peripheral anastomosis/patient mean \pm SD	3.5 \pm 1.1	3.5 \pm 1.0	0.373
EF % median (Q1, Q3)	60 (50, 60)	60 (50, 65)	<0.001*
Indication for Angiography n, (%)			0.916
Re-angina	501 (81.1)	667 (80.8)	
MI	117 (18.9)	158 (19.2)	

306 * Mann-Whitney U test was used. Values are presented as mean \pm standard deviation for
307 normal distributed variables, median (Q1, Q3) for non-normal distributed variables, or n (%).

308 EF: ejection fraction. MI: myocardial infarction.

309

310 Table 5: Patency rate per patient of no-touch and conventional vein grafts, and patency of
311 arterial grafts divided by type of vein graft

Patient characteristics	No-touch	Conventional	p-value
No. of patients	618	825	
Patency/patient of Vein Grafts, %	70.7	46.7	<0.001
Patency/patient of Arterial grafts, %	86.4	86.3	0.954
Patency/patient of LITA, %	98.4	95.9	0.006

312 Values are presented as %. LITA: left internal thoracic artery.

313

314 Table 6: Patency in no-touch and conventional vein grafts divided by type of graft

Patient characteristics	No-touch	Conventional	p-value
No. of Grafts	908	1656	
Graft Patency	75.9	63.5	<0.001
Single	75.6	62.8	<0.001
Sequential	76.0	65.3	<0.001

315 Values are presented as %.

316

317 Table 7: Patency of no-touch and conventional vein grafts divided by territory of distribution
318 and sub-divided by graft type (single or sequential)


Patient characteristics	No-touch	Conventional	p-value
To LAD	58/70 (82.9)	45/66 (68.2)	0.046
Single	30/36 (83.3)	35/49 (71.4)	0.201
Sequential	28/34 (82.4)	10/17 (58.8)	0.093*
To DA	317/360 (88.1)	353/519 (68.0)	<0.001
Single	44/54 (81.5)	160/273 (58.6)	0.002
Sequential	273/306 (89.2)	193/246 (78.5)	<0.001
To MA	402/468 (85.9)	529/673 (78.6)	0.002
Single	90/104 (86.5)	270/339 (79.6)	0.115
Sequential	312/364 (85.7)	259/334 (77.5)	0.005
To RCA	285/404 (70.5)	355/623 (57.0)	<0.001
Single	183/256 (71.5)	307/549 (55.9)	<0.001
Sequential	102/148 (68.9)	48/74 (64.9)	0.543

319 Values are presented as n, (%). LAD: left anterior descending, DA: diagonal artery,

320 MA: marginal artery, RCA: right coronary artery. * Fisher's exact test.

321

322 Figure 1



323

324 A: arterial graft alone; C: conventional graft; CABG: coronary artery bypass grafting; NT:

325 no-touch graft; PCI: percutaneous coronary intervention; SVG: saphenous vein graft.

326 References

- 327 1. WHO. The top 10 causes of death. 2020 [cited Available from: [https://www.who.int/news-](https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death)
328 [room/fact-sheets/detail/the-top-10-causes-of-death](https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death).
329 2. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG,
330 Guyton RA, Hollenberg SM, et al. 2015 ACC/AHA/SCAI Focused Update on Primary
331 Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction:
332 An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
333 and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial
334 Infarction. *J Am Coll Cardiol* 2016;67(10):1235-50.
335 3. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet
336 J-P, Falk V, Head SJHj. 2018 ESC/EACTS guidelines on myocardial revascularization.
337 2019;40(2):87-165.
338 4. Patel MR, Calhoun JH, Dehmer GJ, Grantham JA, Maddox TM, Maron DJ, Smith PKJotACoC.
339 ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 appropriate use criteria for coronary
340 revascularization in patients with stable ischemic heart disease: a report of the American
341 College of Cardiology appropriate use criteria task force, American Association for Thoracic
342 Surgery, American Heart Association, American Society of Echocardiography, American
343 Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions,
344 Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons.
345 2017;69(17):2212-41.
346 5. Farkouh ME, Domanski M, Dangas GD, Godoy LC, Mack MJ, Siami FS, Hamza TH, Shah B,
347 Stefanini GG, Sidhu MSJotACoC. Long-term survival following multivessel revascularization
348 in patients with diabetes: the FREEDOM follow-on study. 2019;73(6):629-38.
349 6. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ,
350 Rosenberg Y, Solomon SD, et al. Strategies for multivessel revascularization in patients with
351 diabetes. *N Engl J Med* 2012;367(25):2375-84.
352 7. Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A, Mack MJ, Holmes
353 DR, Jr., Morel MA, Van Dyck N, et al. Coronary artery bypass graft surgery versus
354 percutaneous coronary intervention in patients with three-vessel disease and left main
355 coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. *Lancet*
356 2013;381(9867):629-38.
357 8. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Stahle E, Feldman
358 TE, van den Brand M, Bass EJ, et al. Percutaneous coronary intervention versus coronary-
359 artery bypass grafting for severe coronary artery disease. *N Engl J Med* 2009;360(10):961-72.
360 9. Thuijs D, Kappetein AP, Serruys PW, Mohr FW, Morice MC, Mack MJ, Holmes DR, Jr., Curzen
361 N, Davierwala P, Noack T, et al. Percutaneous coronary intervention versus coronary artery
362 bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year
363 follow-up of the multicentre randomised controlled SYNTAX trial. *Lancet*
364 2019;394(10206):1325-34.
365 10. Souza D. A new no-touch preparation technique. Technical notes. *Scand J Thorac Cardiovasc*
366 *Surg* 1996;30(1):41-4.
367 11. Ramos De Souza D, Dashwood MR, Samano N. Saphenous vein graft harvesting and patency:
368 No-touch harvesting is the answer. *J Thorac Cardiovasc Surg* 2017;154(4):1300-1.
369 12. Samano N, Dashwood M, Souza D. No-touch vein grafts and the destiny of venous
370 revascularization in coronary artery bypass grafting-a 25(th) anniversary perspective. *Ann*
371 *Cardiothorac Surg* 2018;7(5):681-5.
372 13. Johansson BL, Souza DS, Bodin L, Filbey D, Loesch A, Geijer H, Bojö L. Slower progression of
373 atherosclerosis in vein grafts harvested with 'no touch' technique compared with
374 conventional harvesting technique in coronary artery bypass grafting: an angiographic and
375 intravascular ultrasound study. *Eur J Cardiothorac Surg* 2010;38(4):414-9.

- 376 14. Samano N, Geijer H, Liden M, Fremes S, Bodin L, Souza D. The no-touch saphenous vein for
377 coronary artery bypass grafting maintains a patency, after 16 years, comparable to the left
378 internal thoracic artery: A randomized trial. *J Thorac Cardiovasc Surg* 2015;150(4):880-8.
- 379 15. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C,
380 Schlesselman JJ, Egger M. Strengthening the Reporting of Observational Studies in
381 Epidemiology (STROBE): explanation and elaboration. *PLoS Med* 2007;4(10):e297.
- 382 16. Souza DS, Dashwood MR, Tsui JC, Filbey D, Bodin L, Johansson B, Borowiec J. Improved
383 patency in vein grafts harvested with surrounding tissue: results of a randomized study using
384 three harvesting techniques. *Ann Thorac Surg* 2002;73(4):1189-95.
- 385 17. Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen
386 MG, DiMaio JM, Don CW, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery
387 Revascularization: Executive Summary: A Report of the American College of
388 Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
389 *Circulation* 2022;145(3):e4-e17.
- 390 18. Swedeheart. 2020 [cited 2020 30 November 2020]. Available from:
391 <https://www.ucr.uu.se/swedeheart/>.
- 392 19. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft
393 fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and
394 reoperation in 1,388 patients during 25 years. *J Am Coll Cardiol* 1996;28(3):616-26.
- 395 20. Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, Copeland JG, Thottapurathu L, Krasnicka B,
396 Ellis N, Anderson RJ, et al. Long-term patency of saphenous vein and left internal mammary
397 artery grafts after coronary artery bypass surgery: results from a Department of Veterans
398 Affairs Cooperative Study. *J Am Coll Cardiol* 2004;44(11):2149-56.
- 399 21. Shah PJ, Gordon I, Fuller J, Seevanayagam S, Rosalion A, Tatoulis J, Raman JS, Buxton BF.
400 Factors affecting saphenous vein graft patency: clinical and angiographic study in 1402
401 symptomatic patients operated on between 1977 and 1999. *J Thorac Cardiovasc Surg*
402 2003;126(6):1972-7.
- 403 22. Deb S, Singh SK, de Souza D, Chu MWA, Whitlock R, Meyer SR, Verma S, Jeppsson A, Al-Saleh
404 A, Brady K, et al. SUPERIOR SVG: no touch saphenous harvesting to improve patency
405 following coronary bypass grafting (a multi-Centre randomized control trial, NCT01047449).
406 *J Cardiothorac Surg* 2019;14(1):85.
- 407 23. Samano N, Pinheiro BB, Souza D. Surgical Aspects of No-Touch Saphenous Vein Graft
408 Harvesting in CABG: Clinical and Angiographic Follow-Up at 3 Months. *Braz J Cardiovasc Surg*
409 2019;34(1):98-100.
- 410 24. Souza DS, Johansson B, Bojö L, Karlsson R, Geijer H, Filbey D, Bodin L, Arbeus M, Dashwood
411 MR. Harvesting the saphenous vein with surrounding tissue for CABG provides long-term
412 graft patency comparable to the left internal thoracic artery: results of a randomized
413 longitudinal trial. *J Thorac Cardiovasc Surg* 2006;132(2):373-8.
- 414 25. Tian M, Wang X, Sun H, Feng W, Song Y, Lu F, Wang L, Wang Y, Xu B, Wang H, et al. No-
415 Touch Versus Conventional Vein Harvesting Techniques at 12 Months After Coronary Artery
416 Bypass Grafting Surgery: Multicenter Randomized, Controlled Trial. *Circulation*
417 2021;144(14):1120-9.
- 418 26. Ferrari G, Geijer H, Cao Y, Graf U, Bojö L, Carlsson R, Souza D, Samano N. Long-term results
419 of percutaneous coronary intervention in no-touch vein grafts are significantly better than in
420 conventional vein grafts. *Perfusion* 2024;2676591241230012.
- 421 27. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck
422 MR, Galbraith M, et al. 2023 ESC Guidelines for the management of acute coronary
423 syndromes. *Eur Heart J* 2023.
- 424